AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Cardiff Oncology’s stock price jumped 50% following the Phase II data. Credit: aslysun / Shutterstock. US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial ...

Patients saw an average 14.5% relative improvement in disease-free survival when compared with the placebo arm of the study after 54 months. Credit: shutterstock / Peakstock Candel Therapeutics’s ...

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

A clinical benefit rate of 62.5% was noted among subjects with both mutant and wild-type oestrogen receptor alpha gene disease. Credit: Andrei_R/Shutterstock. Arvinas and Pfizer have shared ...

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

The UK is seeing an overall improvement in its desirability as a clinical trials location, but it still has ground to make up.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.